Profile data is unavailable for this security.
About the company
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.
- Revenue in USD (TTM)2.78m
- Net income in USD-40.32m
- Incorporated2020
- Employees57.00
- LocationSAB Biotherapeutics Inc777 W 41St St, Suite 401MIAMI BEACH 33140United StatesUSA
- Phone+1 (305) 845-2813
- Fax+1 (302) 636-5454
- Websitehttps://www.sab.bio/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palatin Technologies, Inc. | 5.90m | -32.20m | 21.95m | 34.00 | -- | 13.90 | -- | 3.72 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
Geovax Labs Inc | 300.68k | -26.92m | 22.56m | 17.00 | -- | -- | -- | 75.03 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Hcw Biologics Inc | 3.92m | -38.37m | 22.69m | 45.00 | -- | -- | -- | 5.78 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.78m | -40.32m | 23.63m | 57.00 | -- | 0.5123 | -- | 8.50 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Biora Therapeutics Inc | 860.00k | -86.81m | 23.74m | 58.00 | -- | -- | -- | 27.60 | -5.57 | -5.56 | 0.024 | -2.49 | 0.0253 | -- | 1.05 | 14,827.59 | -255.56 | -122.84 | -- | -369.01 | -- | -- | -10,094.19 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
RenovoRx Inc | 0.00 | -8.11m | 23.75m | 8.00 | -- | 2.56 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Bolt Biotherapeutics Inc | 11.17m | -66.17m | 23.79m | 100.00 | -- | 0.2771 | -- | 2.13 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
Unity Biotechnology Inc | 0.00 | -27.86m | 23.92m | 19.00 | -- | 1.21 | -- | -- | -1.80 | -1.80 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.05 | -47.21 | -45.11 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Cognition Therapeutics Inc | 0.00 | -31.08m | 24.04m | 25.00 | -- | 1.04 | -- | -- | -0.9317 | -0.9317 | 0.00 | 0.5736 | 0.00 | -- | -- | 0.00 | -79.36 | -- | -104.49 | -- | -- | -- | -- | -- | -- | -263.29 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -21.07m | 24.54m | 25.00 | -- | 0.6418 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Marker Therapeutics Inc | 3.73m | -10.31m | 24.72m | 8.00 | -- | 2.54 | -- | 6.63 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Iterum Therapeutics PLC | 0.00 | -28.34m | 24.75m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Promis Neurosciences Inc | 0.00 | -12.20m | 24.96m | 6.00 | -- | -- | -- | -- | -0.6924 | -0.6924 | 0.00 | -0.1201 | 0.00 | -- | -- | 0.00 | -839.15 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | -- | -- | -- | -- | 26.85 | -- | -- | -- |
Nuo Therapeutics Inc | 1.03m | -2.69m | 25.01m | -- | -- | 41.78 | -- | 24.31 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Surrozen Inc | 0.00 | -53.45m | 25.68m | 42.00 | -- | 4.24 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
IGC Pharma Inc | 1.06m | -13.30m | 25.72m | 67.00 | -- | 3.26 | -- | 24.22 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 30 Jun 2024 | 917.83k | 9.95% |
RTW Investments LPas of 30 Jun 2024 | 766.95k | 8.31% |
Marshall Wace LLPas of 30 Jun 2024 | 459.17k | 4.98% |
Sessa Capital IM LPas of 30 Jun 2024 | 458.46k | 4.97% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 275.20k | 2.98% |
Geode Capital Management LLCas of 30 Jun 2024 | 59.42k | 0.64% |
Millennium Management LLCas of 30 Jun 2024 | 52.78k | 0.57% |
Pathstone Family Office LLCas of 30 Jun 2024 | 50.65k | 0.55% |
First Manhattan Co LLCas of 30 Jun 2024 | 24.58k | 0.27% |
First Premier Bank (Investment Management)as of 30 Jun 2024 | 19.39k | 0.21% |